ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden)
ESPRESSO
1 other identifier
observational
13,000,000
0 countries
N/A
Brief Summary
The ESPRESSO study is a collection of data from all computerised gastrointestinal histopathology reports in Sweden. This allows us to study risk factors for gastrointestinal disease, as well as the prognosis of gastrointestinal disease. A review of the study has been published here: https://pubmed.ncbi.nlm.nih.gov/30679926/
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 1965
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 1965
CompletedFirst Submitted
Initial submission to the registry
March 27, 2024
CompletedFirst Posted
Study publicly available on registry
April 17, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 17, 2043
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 17, 2043
April 17, 2024
April 1, 2024
78.4 years
March 27, 2024
April 15, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Incident Mortality [especially rates]
Record of death in the Swedish Cause of Death Register. Please note: Different sub-projects will have different primary outcomes.
Currently up until 2022
Secondary Outcomes (4)
Incident Cancer
Currently up until 2022
Incident Cardiovascular disease
Currently up until 2022
Incident Neurological disease
Currently up until 2022
Incident Autoimmune diseases
Currently up until 2022
Other Outcomes (1)
Please note that the recorded outcomes above are examples. Other outcomes may also be studied.
Currently up until 2022
Interventions
This study has no interventions.
Eligibility Criteria
Males 45.8% Median age at biopsy: 58 years
You may qualify if:
- Any person with a computerised histopathology record from the gastrointestinal tract including the liver, gallbladder and the pancreas.
- Matched controls to any person with the above histopathology record.
- Spouses and first-degree relatives to any of the above.
You may not qualify if:
- None
- (this is a registry-based study)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Ludvigsson JF, Lashkariani M. Cohort profile: ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden). Clin Epidemiol. 2019 Jan 14;11:101-114. doi: 10.2147/CLEP.S191914. eCollection 2019.
PMID: 30679926RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jonas F Ludvigsson, MD, PhD
Karolinska Institutet
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
March 27, 2024
First Posted
April 17, 2024
Study Start
January 1, 1965
Primary Completion (Estimated)
May 17, 2043
Study Completion (Estimated)
May 17, 2043
Last Updated
April 17, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share
No plan to make individual participant data (IPD) available to other researchers. (such sharing is not consistent with the rules from the Swedish government agency: Statistics Sweden).